Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Teva Pharma B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands
PROVIGIL 100 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. The tablets are white to off-white, 13 × 6 mm, capsule-shaped and debossed with ‘100’ on one side. |
Each tablet contains 100 mg of modafinil.
Excipient(s) with known effect: Each tablet contains 68mg of anhydrous lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Modafinil |
Modafinil promotes wakefulness in a variety of species, including man. The precise mechanism(s) through which modafinil promotes wakefulness is unknown. |
| List of Excipients |
|---|
|
Lactose monohydrate |
Opaque PVC/PVDC/aluminium blisters.
Packs of 10, 20, 30, 50, 60, 90, 100 or 120 tablets.
Not all pack sizes may be marketed.
Teva Pharma B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands
PL 14776/0098
Date of first authorisation: 14 October 1997
Date of latest renewal: 24 June 2017
| Drug | Countries | |
|---|---|---|
| PROVIGIL | Estonia, Ireland, Israel, Malta, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
